Novel translational model for breast cancer chemoprevention study: Accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 10, 2000, Pages 1087-1090

  Singletary, Eva ^a   Lieberman, Ron ^b   Atkinson, Nealy ^a   Sneige, Nour ^a   Sahin, Ayse ^a   Tolley, Susanne ^a   Colchin, Mary ^a   Bevers, Therese ^a   Stelling, Carol ^a   Fornage, Bruno ^a   Fritsche, Herbert ^a   Hittelman, Walter ^a   Kelloff, Gary ^b   Lippman, Scott M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FENRETINIDE; KI 67 ANTIGEN; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL TRIAL; EARLY CANCER; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MODEL; PATIENT ATTITUDE; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLE; TUMOR VOLUME;

ADULT; AGED; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMAN; MIDDLE AGE; PATIENT SELECTION; PROSPECTIVE STUDIES; RESEARCH DESIGN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0033792342     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: Long-term follow-up and causes of death
2. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-Study
4. N-(4-Hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat
5. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer
6. Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation
7. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats
8. Growth inhibition by retinol of a human breast carcinoma cell line in vitro and in athymic mice
9. Development of breast cancer chemopreventive drugs
10. Accrual to clinical trials
11. Viability of cancer clinical research: Patient accrual, coverage, and reimbursement
12. Models for early chemoprevention trials in breast cancer
13. Patient participation and compliance in cancer chemoprevention trials: Issues and concerns
14. Recruitment for complementary/alternative medicine trials: Who participates after breast cancer
15. Reducing patient eligibility criteria in cancer clinical trials
16. A study in contrasts: Eligibility criteria in a twenty-year sample of NSABP and POG clinical trials
17. Cancer patient accessions into clinical trials: A pilot investigation into some patient and physician determinants of entry
18. Reasons for nonentry in randomized clinical trials for breast cancer: A single institution study